is semaglutide fda approved for obesity Approves Oral as First GLP-1 Pill Weight Loss GLP-1 Medications for Weight Loss:

The standard marker for harmful cholesterol-particle number (apolipoprotein-B, or apoB) fell by around 24%

Key Takeaways Some patients may tolerate GLP-1 medications better with split dosing Smaller divided doses may reduce nausea, bloating, fatigue, and appetite swings in select individuals Twice-weekly dosing is generally considered off-label Not every patient benefits from dose splitting Long-term success depends on individualized care, nutrition, sleep, and strength training Patients should never change dosing schedules without provider guidance Splitting GLP-1 doses into twice-weekly injections is an off-label, occasionally helpful strategy for very sensitive patientsbut it is not an evidence-based standard for managing side effects

However, FDA approval is limited to pen used with Zepbound (tirzepatide), while its sibling brand, Mounjaro, is marketed in India

Rapid weight loss, whether from GLP-1 medications or other causes, can affect mineral stores through reduced intake, altered absorption, and changes in body composition that release stored minerals

Mild hyperhomocysteinemia was not associated with higher rates of stroke